IDH2 and cholangiocarcinoma: Notably, IDH1 and IDH2 mutations, which are common (approximately 25%) in cholangiocarcinoma (CCA) patients of Western populations 21, were observed in only 7% and 2% of Chinese BTC patients, respectively.